Sic1 inhibitors belong to a specific chemical class of compounds that have shown significant interest in scientific research due to their potential role in regulating cell cycle progression. Sic1, short for "Start-Independent Cell cycle protein 1," is a crucial protein involved in cell cycle control in eukaryotic cells. It plays a pivotal role in preventing cell cycle initiation until the cell has undergone essential preparatory steps. Sic1 inhibitors are designed to selectively target and modulate the activity of Sic1, ultimately impacting cell cycle regulation.
The mechanism of Sic1 inhibitors involves interfering with the normal function of Sic1, leading to alterations in the timing and progression of the cell cycle. By inhibiting the activity of Sic1, these compounds could potentially disrupt the regulatory checkpoints, which might result in abnormal cell cycle progression. Researchers have been keen on exploring the molecular interactions between Sic1 and its inhibitors to better understand the underlying cellular processes. Due to their distinct chemical structure and specific targeting of Sic1, these inhibitors offer valuable insights into the intricate mechanisms governing cell cycle regulation. Their study has implications in fundamental cell biology, offering potential applications in various fields, such as cell growth control and cell differentiation. Their investigation continues to shed light on the intricate machinery that orchestrates cell cycle progression in eukaryotic organisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
An inhibitor of multiple cyclin-dependent kinases (CDKs) including CDK2, CDK7, and CDK9. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
A potent CDK inhibitor with activity against CDK1, CDK2, CDK5, and CDK9. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
A selective inhibitor of CDK4 and CDK6, used in combination with hormonal therapy for certain types of breast cancer. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
An investigational CDK inhibitor with selectivity for CDK4 and CDK9. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
A potent inhibitor of multiple CDKs, including CDK1, CDK2, CDK4, and CDK9. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
A small-molecule inhibitor of CDK2 and CDK5. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
A pan-CDK inhibitor that targets CDK1, CDK2, CDK4, CDK6, and CDK9. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
A potent and selective inhibitor of CDK2, CDK7, and CDK9. | ||||||